

NAME: Jingyuan Yang



PHOTO:

[PRESENT POSITIONS]

Executive Director of Biostatistics, Allergan

[FORMER POSITIONS]

Director of Biostatistics, Allergan

Associate Director of Biostatistics, Allergan

Senior Biostatistics Manager, Amgen

Biostatistics Manager, Amgen

[DEGREES]

PhD in Biostatistics, The Ohio State University

[FIELDS OF MAJOR STATISTICAL ACTIVITIES]

Design and analysis of clinical trials

Statistical genetics

[SELECTED PUBLICATIONS]

Statistics Journal

- J. Yang and S. Lin, Robust partial likelihood approach for detecting imprinting and maternal effects using case-control families, **Annals of Applied Statistics** 7(1): 249-268, 2013
- J. Yang and S. Lin, A likelihood approach for detection of imprinting and in utero maternal effects using general pedigree data, **Biometrics** 68(2): 477-485, 2012
- G. Aras, J. Yang and Y. Shao, On incremental incidence rates in long-term cohort safety studies, **Statistics in Biopharmaceutical Research** 5(3):158-169, 2013
- J. Yang, X. Li and G. Liu, Analysis of zero-inflated count data from clinical trials with potential dropouts, **Statistics in Biopharmaceutical Research** 4(3): 273-283, 2012

- J. Yang and S. Lin, Genome-wide detection of imprinting and heterogeneous maternal effects on high blood pressure using Framingham Heart Study data, **BioMed Central Proceedings 3**(Suppl 7): S125, 2009

Medical Journal

- SJ. Nicholls, R. Puri, T. Anderson, CM. Ballantyne, L. Cho, JJP. Kastelein, W. Koenig, R. Somaratne, H. Kassahun, J. Yang, SM. Wasserman, R. Scott, I. Ungi, J. Podolec, AO. Ophuis, JH. Cornel, M. Borgman, DM. Brennan, SE. Nissen, Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV), **JAMA** 316(22): 2373-2384, 2016
- R. Puri, SE. Nissen, R. Somaratne, L. Cho, JJP. Kastelein, CM. Ballantyne, W. Koenig, TJ. Anderson, J. Yang, H. Kassahun, SM. Wasserman, R. Scott, M. Borgman, and SJ. Nicholls, Impact of PCSK9 inhibition on coronary atheroma progression: Rationale and design of Global Assessment of Plaque Regression with a PCSK9 Antibody as Measured by Intravascular Ultrasound (GLAGOV), **American Heart Journal** 176: 83-92, 2016
- M. Koren, P. Lundqvist, M. Bolognese, J. Neutel, ML. Monsalvo, J. Yang, J. Kim, R. Scott, SM. Wasserman, and H. Bays, Anti-PCSK9 monotherapy for hypercholesterolemia: the MENDEL-2 randomized, controlled phase III clinical trial of evolocumab, **Journal of the American College of Cardiology** 63(23): 2531-2540, 2014
- E. Stein, R. Giugliano, M. Koren, F. Raal, E. Roth, R. Weiss, D. Sullivan, SM. Wasserman, R. Somaratne, J. Kim, J. Yang, T. Liu, M. Albizem, R. Scott, and M. Sabatine, Efficacy and safety of evolocumab (AMG 145), a full human monoclonal antibody to PCSK9, in hyperlipidaemic patients on various background lipid therapies: pooled analysis of 1359 patients in four phase 2 trials, **European Heart Journal** 35(33):2249-2259, 2014

[ICSA ACTIVITIES]

New member

[PROFESSIONAL COMMITTEES]

Member of ASA Orange County Long Beach chapter

[HONORS AND AWARDS]

[STATEMENT]

Dear Executive Director of the ICOSA,

As a Chinese statistician who works in biopharmaceutical industry for more than 10 years, I would like to serve as a Board Member of the International Chinese Statistical Association (ICOSA) to give back to the community.

Even though I am a relatively new member of the ICOSA, I carefully read the objectives and by-laws of the association to make sure I am aligned with those goals and clear about the responsibilities as a Board Member. Serving as a Board Member would be a great opportunity for me to apply my professional skills (including technical knowledge and managerial/leadership experience) to promote communication and collaboration among statisticians who work in industry, academia, and government and who are still in training. Although I do not have direct experience as a Board Member of any other professional organizations, I am on the leadership team of the Statistical Sciences & Programming department at Allergan. As part of the governance body, I work with other department leaders to come up with and implement operational strategies. I believe this experience would enable me to succeed on the similar duty as a Board Member of ICOSA. I would be honored to work with other Board Members to make strategic plan to steer the organization. I also commit to attend the Board Meetings and annual ICOSA symposiums when travel is feasible and fulfill any other responsibilities of a Board Member.

I am confident that you'll find me a good fit as a Board Member of the ICOSA. Please feel free to let me know if further information is needed and I look forward to hearing the selection outcome.

Regards,

Jingyuan Yang

May 6th, 2020